We have demonstrated that the HNK-1 carbohydrate is required for the structural and functional development of the mammalian nervous system, such as the maturation of dendritic spines and acquisition of synaptic plasticity, respectively (8) (9) (10) . The HNK-1 carbohydrate has a unique structural feature, i.e., a sulfated glucuronic acid is attached to the non-reducing terminal of an N-acetyllactosamine residue (11, 12) . Because the N-acetyllactosamine structure is commonly found in various glycoproteins and glycolipids, two glucoronyltransferases (GlcAT-P and GlcAT-S) and a sulfotransferase (HNK-1ST) had been cloned and characterized as key enzymes for the biosynthesis.
(7). GlcAT-P or GlcAT-S and HNK-1ST interact closely as a functional complex, cooperatively synthesizing the HNK-1 carbohydrate (13).
However, while GlcAT-P and GlcAT-S show a highly restricted tissue distribution (14, 15) , HNK-1ST is more ubiquitous and exists in several tissues where neither GlcAT-P nor GlcAT-S is observed, including skeletal muscle, heart, spleen, and reproductive organs (16, 17) . These findings suggest that HNK-1ST has another function, which might underlie the RA-mediated melanoma differentiation.
α-Dystroglycan (α-DG) is a ubiquitously expressed peripheral membrane glycoprotein, which serves as a receptor for ECM components including laminin, agrin and perlecan (18, 19) . α-DG is anchored on the plasma membrane by β-DG, which interacts with cytoskeletal proteins, together comprising the DG complex that provides physical links between the cell and basal lamina (18) (19) (20) .
α-DG undergoes extensive glycosylation in a tissue-specific manner (18, 19, 21) , and the attached glycan acts as a critical mediator of the interaction between α-DG and its ligands (22, 23) . Although the precise structure of the glycan important for the function of α-DG has not completely been determined, aberrant glycosylation of α-DG has already been identified in the pathogenesis of several types of congenital muscular dystrophy (CMD)
accompanied by brain and eye malformations (24, 25 (32, 33) .
In this report, we show that HNK-1ST containing human DAG1 cDNA as a template, and subcloned into pEF-Fc. Expression plasmids for FLAG-GlcAT-P, pIRES-GlcAT-P/HNK-1ST
4
(pIRES-P/ST), HNK-1ST-EGFP, C4ST1-EGFP and GalNAc4ST1-EGFP were described previously (13 Construction of R189A-EGFP, the plasmid encoding the R189A mutant of HNK-1ST, was described previously (34) . GGAAGGGCTCATGACCACAGTCCAT and CATACTTGGCAGGTTTCTCCAGGCG.
Quantitative PCR was performed with a Chromo 4
Real-Time System (Bio-Rad) using SYBR green I.
Each sample was run in triplicate and GAPDH mRNA was amplified from the same sample to normalize the expression level. Following treatment with 1 µM RA, a marked increase of HNK-1ST mRNA was detected using RT-PCR (Fig. 1, A and B) , consistent with a previous report (6) . However, neither of the glucuronyltransferases (GlcAT-P and GlcAT-S) responsible for producing HNK-1 was observed ( (Fig. 1D) . Moreover, RA treatment eliminated the susceptibility to the IIH6 mAb ( mAb, as a broad and high-molecular band (Fig. 3A) .
However, when α-DG-Fc was co-transfected with HNK-1ST-EGFP, there was a remarkable decrease in the laminin-binding activity and almost complete loss of IIH6 immunoreactivity, in spite of the comparable expression of LARGE-myc (Fig. 3, A and B). The results obtained from this simple expression system clearly demonstrated that HNK-1ST actually inhibits the formation of the glycan on α-DG. Furthermore, to explore whether a similar effect could be found with other homologous sulfotransferases, we co-transfected LARGE-myc and C4ST1-EGFP or GalNAc4ST1-EGFP, both of which belong to the HNK-1ST family (39, 40) .
LARGE-dependent glycosylation of α-DG was not suppressed by either C4ST1 or GalNAc4ST1 (Fig. 4, A and B), indicating that the α-DG-modulating function is specific to HNK-1ST. To further confirm this evidence, we carried out an inhibition assay for PAPS production using sodium chlorate (NaClO 3 ). NaClO 3 is a specific inhibitor of 
The interaction between α-DG and LARGE is unaltered in the presence of HNK-1ST -

DISCUSSION
Melanoma is one of the most malignant tumors,
showing high metastatic ability and a rapid progression, which leads to a poor prognosis.
Expression of the HNK-1 epitope is found in both primary and metastatic lesions in cases of melanoma (45, 46) and correlates with metastatic behavior (46) . has the ability to transfer a sulfate group to the C-3 position of terminal GlcA, at which xylose is transferred; therefore, it makes sense that HNK-1ST inhibits IIH6-reactive glycan produced by LARGE.
Our data presented in this study are highly important for understanding dystroglycan function via its glycosylation.
In mammals, an apparent molecular weight of α-DG varies from highly limited (about 120 kDa, e.g. brain) to rather broad (120-200 kDa, e.g. muscle) due to its glycosylation in a tissue-dependent manner (18, 19, 21) . In contrast, in experiments using cell lines, forced expression of LARGE always yields an extensively glycosylated α-DG that appears as a band of ≥200 kDa on SDS-PAGE (Fig. 2-5 ) (37, 38, 41) , implying the presence of an unidentified machinery that negatively regulates the glycosylation of α-DG in vivo. Hence, we propose HNK-1ST to be one such suppressive factor for α-DG function, acting as a "molecular brake" to generate properly glycosylated α-DG. In this regard, future studies might identify a pathogenic mutation of HNK-1ST in CMD patients, which causes hyperactivation of HNK-1ST resulting in hypoglycosylation of α-DG.
Investigating the α-DG-modulating function of HNK-1ST could be a powerful means of uncovering the regulatory system of α-DG glycosylation, contributing to the development of therapeutic strategies for glycosylation-defective CMDs.
